6 hours ago
1
SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the "Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at four upcoming investor conferences in May and June.
2025 Bank of America Health Care Conference
- Location - Las Vegas, NV
- Fireside Chat - Wednesday, May 14 at 3pm PT / 6pm ET
45th Annual William Blair Growth Stock Conference
- Location - Chicago, IL
- Presentation - Wednesday, June 4 at 10am CT / 11am ET
2025 Jefferies Global Healthcare Conference
- Location - New York City, NY
- Fireside Chat - Thursday, June 5 at 8:45m ET
2025 Truist Med-Tech Conference
Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
- Location - Boston, MA
- Fireside Chat - Tuesday, June 17 at 8:40am ET
A live webcast of each event, as well as an archived recording, will be available on the "Investors” section of the Company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics' mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
